Restorative Neurology, Drugs and Recovery Following Stroke
Stroke 21:1636-1640, Goldstein,L.B.&Davis,J.N., 1990
NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
Cognitive Impairment & Mortality in a Cohort of Elderly People
BMJ 312:608-611, Gale,C.R.,et al, 1996
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Effect of Demebon on Cognition, Activities of Daily Living, Behavior, and Global Function in Patients With Mild-To-Moderate Alzheimers Disease: A Randomised, Double-Blind, Placebo-Controlled Study
Lancet 372:207-215,179, Doody, R.S.,et al., 2008
The Neuroprotective Effects of Caffeine: A Prospective Population Study (the Three City Study)
Neurol 69:536-545, Ritchie,K.,et al, 2007
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Therapeutic Hypothermia for Global and Focal Ischemic Brain Injury-A Cool Way to Improve Neurologic Outcomes
Neurologist 13:331-342, Hoesch,R.E. &Geocadin,R., 2007
Piracetam for Acute Ischemic Stroke
Stroke 37:2191-2192, Ricci,S.,et al, 2006
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
Calcium Antagnosits in Aneurysmal Subarachnoid Hemorrhage
Stroke 36:1816-1817, Rinkel,G.J.E.,et al, 2005
Lipid-Lowering Agent Use at Ischemic Stroke Onset is Associated with Decreased Mortality
Neurol 65:253-258, Elkind,M.S.V.,et al, 2005
Magnesium for Acute Stroke (Intravenous Magnesium Efficacy in Stroke Trial):Randomised Controlled Trial
Lancet 363:439-445,414, Goldstein,L.B., 2004
Alcohol Consumption and Risk of Stroke
JAMA 289:579-588, Reynolds,K.,et al, 2003
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 34:1056-1083, Adams,H.P.,et al, 2003
Apoptosis and Caspases in Neurodegenerative Diseases
NEJM 348:1365-1375, Friedlander,R.M., 2003
Alcohol Consumption and Risk of Dementia: the Rotterdam Study
Lancet 359:281-286, Ruitenberg,A.,et al, 2002
Alcohol Consumption and Risk of Ischemic Stroke
Stroke 33:907-912,890, Djousse,L,et al, 2002
Prognostic Significance of Uric Acid Serum Concentration in Patients with Acute Ischemic Stroke
Stroke 33:1048-1052, Chamorro,A.,et al, 2002
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Calcium Antagonists for Ischemic Stroke
Stroke 32:570-576, Horn,J. &Limburg,M., 2001
Human Albumin Therapy of Acute Ischemic Stroke
Stroke 32:553-560, Belayev,L.,et al, 2001
Cooling for Acute Ischemic Brain Damage (COOL AID)
Stroke 32:1847-1854, Krieger,D.W.,et al, 2001
New Imaging Strategies for Patient Selection for Thrombolytic and Neuroprotective Therapies
Neurol 57:S48-S52, Warach,S., 2001
Aptiganel Hydrochloride in Acute Ischemic Stroke
JAMA 286:2673-2682,2718, Albers,G.W.,et al, 2001
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Ischemic Core and Penumbra in Human Stroke
Stroke 30:93-99, Kaufmann,A.M.,et al, 1999
Neuroprotective Properties of Statins in Cerebral Ischemia and Stroke
Stroke 30:1969-1973, Vaughan,C.J.&Delanty,N., 1999
Combating Hyperthermia in Acute Stroke, A Significant Clinical Concern
Stroke 29:529-534, Ginsberg,M.D.&Busto,R., 1998
Duration of Neuroprotective Treatment for Ischemic Stroke
Stroke 29:535-542, Dyker,A.G.&Lees,K.R., 1998
Further Evolution Toward Effective Therapy for Acute Ischemic Stroke
JAMA 279:1298-1303, 13041998., Fisher,M.&Bogousslavsky,J., 1998
Nonsteroidal Anti-Inflammatory Drug use and Alzheimer-Type Pathology in Aging
Neurol 50:986-990, Mackenzie,I.&Munoz,D.G., 1998
Estrogen-replacement Therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
Neurol 50:996-1002, Baldereschi,M.,et al, 1998
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Characterizing the Target of Acute Stroke Therapy
Stroke 28:866-872, Fisher,M., 1997
Lubeluzole Treatment of Acute Ischemic Stroke
Stroke 28:2338-2346, Grotta,J., 1997
Treatment of Acute Ischemic Stroke with Piracetam
Stroke 28:2347-2352, DeDeyn,P.P.,et al, 1997
Melatonin"A Clinical Perspective
Ann Neurol 42:545-553, Penev,P.D.,et al, 1997
Lubeluzole in Acute Ischemic Stroke:A Double-Blind Placebo-Controlled Phase II Trial
Stroke 27:76-81, Diener,H.C.,et al, 1996
The Relation Between Fish Consump & Stroke Incidence, NHANES I Epidemiol Study
Arch Int Med 156:537-542, Gillum,R.F.,et al, 1996
Dietary Flavonoids, Antioxidant Vitamins, and Incidence of Stroke
Arch Int Med 154:637-642, Keli,S.O.,et al, 1996
Arthritis & Anti-Inflammatory Agents as Possible Protective Factors for Alzheimer's Dis:Review of 17 Epidemiologic Studies
Neurol 47:425-432, McGeer,P.L.,et al, 1996
Routine Indomethacin Prophylaxis:Has the Time Come
Pediatrics 98:784-785, Bada,H.S., 1996